OBJECTIVES: The study aimed to characterize the pharmacokinetics (PK) of four β-lactams
(piperacillin, ceftazidime, cefepime, and meropenem) in patients comedicated with amikacin …

Background Controversies remain regarding optimal dosing and the need for plasma
concentration measurements when treating intensive care patients with beta‐lactam …

Here we describe the pharmacokinetics of piperacillin administered by continuous infusion
(CI) versus intermittent bolus (IB) dosing in critically ill patients receiving continuous …

Purpose To evaluate target attainment of empirically dosed continuous infusion piperacillin/
tazobactam (TZP) and meropenem (MER) in critically ill patients. Patients and methods …

Augmented renal clearance is commonly observed in septic patients and may result in
insufficient β-lactam serum concentrations. The aims of this study were to evaluate potential …

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• Despite the clinical use of piperacillin
for more than two decades, there are still contradictory reports whether or not the elimination …

Objective Therapeutic failure of antibiotic therapy has been ascribed to pharmacokinetic
alterations in compromised patient populations. The present study, therefore, aimed at …

Critically ill patients with severe infections are at high risk of suboptimal antimicrobial dosing.
The pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobials in these patients …

The clinical efficacy of continuous infusion of piperacillin/tazobactam in critically ill patients
with microbiologically documented infections is currently unknown. We conducted a …

Purpose Standard dosing and intermittent bolus application (IB) are important risk factors for
pharmacokinetic (PK) target non-attainment during empirical treatment with β-lactams in …